Abstract | AIMS: METHODS AND RESULTS: This was a phase 2/3, randomized, double-blind, placebo-controlled trial. Adults with AFL received either a 10 min infusion of 3.0 mg/kg vernakalant (n = 39) or placebo (n = 15). If AFL or AF persisted at the end of a 15 min observation period, a second 10 min infusion of 2.0 mg/kg vernakalant or placebo was administered. The primary efficacy outcome was the proportion of patients who had treatment-induced conversion of AFL to sinus rhythm for a minimum duration of 1 min within 90 min after the start of the first infusion. No patient in the placebo group met the primary outcome. Only one patient receiving vernakalant (1 of 39, 3%) converted to sinus rhythm. A reduced mean absolute ventricular response rate occurred within 50 min in patients receiving vernakalant (mean change from baseline -8.2 b.p.m.) vs. patients receiving placebo (-0.2 b.p.m.) (P = 0.037). A post-hoc analysis revealed that vernakalant increased AFL cycle length by an average of 55 ms, whereas the AFL cycle length was unchanged in the placebo group (P < 0.001). There was no occurrence of 1 : 1 atrio-ventricular conduction. Dysgeusia and sneezing were the most common treatment-related adverse events, consistent with previous reports. CONCLUSION:
Vernakalant did not restore sinus rhythm in patients with AFL. Vernakalant modestly slowed AFL and ventricular response rates, and was well tolerated.
|
Authors | A John Camm, Egon Toft, Christian Torp-Pedersen, Pugazhendhi Vijayaraman, Steen Juul-Moller, John Ip, Gregory N Beatch, Garth Dickinson, D George Wyse, Scene 2 Investigators |
Journal | Europace : European pacing, arrhythmias, and cardiac electrophysiology : journal of the working groups on cardiac pacing, arrhythmias, and cardiac cellular electrophysiology of the European Society of Cardiology
(Europace)
Vol. 14
Issue 6
Pg. 804-9
(Jun 2012)
ISSN: 1532-2092 [Electronic] England |
PMID | 22291438
(Publication Type: Clinical Trial, Phase II, Clinical Trial, Phase III, Journal Article, Multicenter Study, Randomized Controlled Trial, Research Support, Non-U.S. Gov't)
|
Chemical References |
- Anisoles
- Anti-Arrhythmia Agents
- Placebos
- Pyrrolidines
- vernakalant
|
Topics |
- Aged
- Aged, 80 and over
- Anisoles
(administration & dosage, adverse effects)
- Anti-Arrhythmia Agents
(administration & dosage, adverse effects)
- Atrial Flutter
(drug therapy)
- Double-Blind Method
- Dysgeusia
(chemically induced)
- Female
- Heart Atria
(drug effects)
- Heart Conduction System
(drug effects)
- Humans
- Male
- Middle Aged
- Placebos
- Pyrrolidines
(administration & dosage, adverse effects)
- Sneezing
- Treatment Outcome
|